Description:
Ondansetron a 5HT3 receptor antagonist that is selective and competitive work in preventing and overcoming nausea and vomiting caused by sitostatica and radiotherapy treatment.
Composition:
Each 4 ml of ondansetron hydrochloride injection containing the equivalent of 8 mg ondansetron.
Indications:
Prevention of nausea and vomiting due to chemotherapy and radiotherapy and surgery.
Dosage:
Prevention of postoperative nausea and vomiting:
4 mg / i.m. as a single dose or injection i.v. slowly.
Prevention of nausea and vomiting due to chemotherapy.
Adult
Highly emetogenic chemotherapy such as cisplatin. At first given an injection of 8 mg ondansetron i.v. slowly or infused for 15 minutes immediately before chemotherapy, followed by infusion of 1 mg ondansetron / hour during continuously for less than 24 hours or 2 injections of 8 mg iv slowly or infused for 15 minutes with an interval of 4 hours. Or it could be followed by 8 mg orally 2 times a day for less than 5 days.
Less emetogenic chemotherapy, for example siklospamid. Injection i.v. 8 mg ondansetron or infused slowly for 15 minutes immediately before chemotherapy, followed by 8 mg orally 2 times a day for less than 5 days.
Children> 4 years:
5 mg / ml in i.v. for 15 minutes immediately before chemotherapy, followed by giving 4 mg orally every 12 hours for less than 5 days.
Old age:
Ondansetron to be well tolerated in patients aged over 65 years without changing the dose, frequency, or route of administration.
Patients with impaired renal function:
No need for a daily dose adjustment, frequency or route of administration.
Patients with impaired liver function:
Total daily dose should not exceed 8 mg.
Ondansetron a 5HT3 receptor antagonist that is selective and competitive work in preventing and overcoming nausea and vomiting caused by sitostatica and radiotherapy treatment.
Composition:
Each 4 ml of ondansetron hydrochloride injection containing the equivalent of 8 mg ondansetron.
Indications:
Prevention of nausea and vomiting due to chemotherapy and radiotherapy and surgery.
Dosage:
Prevention of postoperative nausea and vomiting:
4 mg / i.m. as a single dose or injection i.v. slowly.
Prevention of nausea and vomiting due to chemotherapy.
Adult
Highly emetogenic chemotherapy such as cisplatin. At first given an injection of 8 mg ondansetron i.v. slowly or infused for 15 minutes immediately before chemotherapy, followed by infusion of 1 mg ondansetron / hour during continuously for less than 24 hours or 2 injections of 8 mg iv slowly or infused for 15 minutes with an interval of 4 hours. Or it could be followed by 8 mg orally 2 times a day for less than 5 days.
Less emetogenic chemotherapy, for example siklospamid. Injection i.v. 8 mg ondansetron or infused slowly for 15 minutes immediately before chemotherapy, followed by 8 mg orally 2 times a day for less than 5 days.
Children> 4 years:
5 mg / ml in i.v. for 15 minutes immediately before chemotherapy, followed by giving 4 mg orally every 12 hours for less than 5 days.
Old age:
Ondansetron to be well tolerated in patients aged over 65 years without changing the dose, frequency, or route of administration.
Patients with impaired renal function:
No need for a daily dose adjustment, frequency or route of administration.
Patients with impaired liver function:
Total daily dose should not exceed 8 mg.
0 comments:
Post a Comment